German chemical and pharmaceutical giant Bayer AG (BYR.L: News ,BAYRY.PK: News ,BAYZF.PK: News ) announced Thursday that its blood thinner Xarelto, known generically as rivaroxaban, in patients with acute coronary syndrome met primary efficacy endpoint in Phase III ATLAS ACS TIMI 51 clinical trial. Xarelto is co-developed by Bayer’s HealthCare subsidiary and drug maker Johnson & Johnson (JNJ: News ). The double blind, placebo controlled Phase III trial of Rivaroxaban plus standard therapy has showed a statistically significant reduction in the rate of events for the primary composite endpoint of cardiovascular death, myocardial infarction and stroke in patients with ACS, compared to standard therapy plus placebo, the company noted.
